Another cytokine of interest in our dataset, IL-6, already has a therapeutic inhibitor named Tocilizumab (anti–IL-6 receptor antibody) commonly used in autoimmune disease and FDA-approved for interstitial lung disease in systemic sclerosis [84]. Here, IL6 is linked to interstitial lung disease.